Measured Wealth Private Client Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Measured Wealth Private Client Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$872K	Sell	3,619 -82	-2%	-$18K	0.21%	76
2026 Q1	$700K	Sell	3,701 -242	-6%	-$42.3K	0.19%	81
2025 Q4	$670K	Sell	3,943 -705	-15%	-$108K	0.18%	77
2025 Q3	$613K	Sell	4,648 -207	-4%	-$24.8K	0.17%	84
2025 Q2	$515K	Buy	4,855 +1,554	+47%	+$169K	0.15%	97
2025 Q1	$410K	Buy	+3,301	New	+$431K	0.13%	109

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Measured Wealth Private Client Group's JAZZ Position: Q2 2026 in Review

Measured Wealth Private Client Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.2% in Q2 2026, selling an estimated $18K and leaving 3,619 shares worth $872K. The position accounts for 0.21% of the portfolio, ranked #76.

Measured Wealth Private Client Group first reported a position in JAZZ in Q1 2025 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Measured Wealth Private Client Group held 3,619 shares of Jazz Pharmaceuticals worth $872K as of Q2 2026.
Measured Wealth Private Client Group sold 82 Jazz Pharmaceuticals shares in Q2 2026, an estimated $18K.
Jazz Pharmaceuticals made up 0.21% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #76 holding.
Measured Wealth Private Client Group first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
645 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.